Clinical Scorecard: Understanding Delays in Diagnosis and Treatment of Primary Central Nervous System Lymphoma: Insights for Neurosurgeons

At a Glance

Key Highlights

• PCNSL accounts for less than 1% of lymphomas and 4% of brain tumors, with median presentation age of 65 years
• Gold standard diagnosis is histopathological confirmation via stereotactic brain biopsy with >91% diagnostic yield
• High-dose methotrexate is cornerstone of treatment, but no international uniform treatment protocol exists

Guideline-Based Recommendations

Diagnosis

• Perform MRI showing solitary or multiple sharply demarcated lesions with homogenous contrast enhancement and diffusion restriction
• Differentiate primary from secondary CNS lymphoma using PET-CT and systemic imaging to exclude systemic lymphoma
• Confirm diagnosis by stereotactic brain biopsy with histopathology and immunohistochemical phenotyping

Management

• Initiate high-dose methotrexate-based chemotherapy as first-line treatment
• Consider patient age, performance status, and comorbidities in treatment planning
• Use interdisciplinary communication for treatment decisions

Monitoring & Follow-up

• Monitor clinical performance and neurological status closely due to rapid disease progression
• Use imaging follow-up to assess treatment response and detect relapse

Risks

• Rapid neurological deterioration at disease onset may limit prognostic use of performance scores
• Older age (>60-70 years) and deep brain structure involvement predict worse prognosis
• Immunodeficiency increases risk and may alter disease presentation

Patient & Prescribing Data

Predominantly elderly patients (>60 years) with or without immunodeficiency

Median survival with treatment is approximately 16 months; 5-year overall survival is 35% in general population but only 6% in elderly (>70 years)

Clinical Best Practices

• Use stereotactic biopsy for definitive diagnosis rather than relying solely on CSF or vitreous fluid analysis
• Employ MRI sequences including T1 post-contrast, FLAIR, DWI, and ADC for lesion characterization
• Exclude systemic lymphoma with PET-CT imaging to avoid unnecessary brain biopsy delays
• Incorporate prognostic models cautiously, considering limitations in performance status scoring
• Engage multidisciplinary teams early for diagnosis, treatment planning, and supportive care

References

• WHO Classification of CNS Tumours 5th edition
• Memorial Sloan Kettering Cancer Centre prognostic model
• International Extranodal Lymphoma Study Group model